Skip to main content
. 2019 Mar 7;68(Suppl 2):S96–S104. doi: 10.1093/cid/ciy1108

Table 2.

Varied Model Parameter Values

Parameter Description Symbol Base Case Range Source
Transmission parameter β .3 .05–.5 [16]
Vaccine efficacy (initial) e .95 .8–1 [15, 16, 23, 24]
Reduction in risk of infection for vaccinated (and protected) individuals e p 1 .5–1 [25]
Duration of protection from vaccination 1/ω1 19.2 years 5–25 years [16, 24]
Fraction symptomatic σ .2 .1–1 [16]
Fraction symptomatic for vaccinated individuals σ V .05 0–.2 [15, 23, 25]}
Fraction treated τ .75 0–1 [16, 26]
Duration of infectiousness with treatment 1/Υ 1 week .5–3 weeks [19]
Rate of treatment-induced/acquired resistance ρ .1 per week .01–2 per week Assumption
Natural recovery rate from first, antimicrobial-resistant infection δ 1,R .2 per week .1–.5 per week [19]
Relative infectiousness of resistant strain(s) r R .9 .5–2 Assumption, [27]
Relative infectiousness of chronic carriers r C .35 .1–1 [16]
Fraction that become carriers from first, antimicrobial-sensitive infection θ 1,S .03 .003–.1 [28]
Fraction that become carriers from first, antimicrobial-resistant infection θ 1,R .03 .003–.1 [28]
Relative rate of recovery from second infection δ 2,S/δ1,S = δ2,R/δ1,R 1 .5–2 Assumption